サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：過活動膀胱治療市場：薬物クラス別、疾患タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
市場調査レポート
商品コード
1266397

過活動膀胱治療市場：薬物クラス別、疾患タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年

Overactive Bladder Treatment Market By Drug Class, By Diseases type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 268 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
過活動膀胱治療市場：薬物クラス別、疾患タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年02月01日
発行: Allied Market Research
ページ情報: 英文 268 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過活動膀胱治療市場は、2021年に24億2,640万米ドルと評価され、2022年から2031年にかけて3.6%のCAGRを示し、2031年には34億6,522万米ドルに達すると推定されています。

過活動膀胱（OAB）は、一群の排尿症状を特徴とする疾患と定義されることがあります。この疾患は、コントロールが困難な頻繁で突然の尿意を引き起こします。また、夜間だけでなく日中にも何度も尿意を感じることがあります。また、意図せず尿が漏れてしまうという特徴もあります。性別に関係なく発症しますが、女性の方がより顕著です。症状としては、緊急かつ制御不能な尿意、不随意的な尿喪失の頻発、頻尿などがあります。これらの症状は症状や個人差によって異なるため、ヘルスケアプロバイダーが診断するのは困難です。過活動膀胱治療薬として、膀胱をリラックスさせ、OABの症状を軽減することができる薬剤がいくつか市場に出回っています。

過活動膀胱治療市場の成長を促す主な要因としては、過活動膀胱の発生率の上昇、膀胱結石や膀胱腫瘍の有病率の上昇、医薬品分野における研究開発活動の増加などが挙げられます。過活動膀胱の発生率は、世界中の人口で大幅に増加しています。この増加は、過活動膀胱の原因となるいくつかの病態の増加に起因しています。脳卒中や多発性硬化症などの神経疾患、頻尿や過多尿を引き起こす尿路感染症、糖尿病、更年期の女性におけるホルモン変化などは、過活動膀胱を引き起こす主要な要因の一部です。

例えば、クリーブランドクリニックが2022年に発表した記事によると、過活動膀胱は米国でよく見られる症状で、最大3,300万人の成人が患っており、その中には男性30%、女性40%もの人が含まれています。また、前立腺肥大、便秘、失禁治療のための手術歴なども過活動膀胱を引き起こす要因の1つです。このように、過活動膀胱を引き起こす膨大な数の要因が存在することで、世界中の人口における過活動膀胱の発生率が増加しています。このため、治療薬の需要が高まり、過活動膀胱治療市場の成長をさらに後押ししています。

さらに、医薬品分野における研究開発活動の活発化も、市場の成長を後押ししています。近年、さまざまな疾患に対する新しい治療法を開発し、革新するための研究活動が非常に活発になってきています。過活動膀胱の病態やその原因を解明するための調査も行われています。詳細な研究に基づき、過活動膀胱の症状をターゲットにした薬剤や分子が科学者によって開発され、過活動膀胱の治療に新たな可能性を提供しています。これにより、市場が活性化すると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • トップインパクトファクター
    • トップインベストメントポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • ライバルの強さ
  • 市場力学
    • 促進要因
      • 過活動膀胱の発生率の増加
      • 膀胱腫瘍および膀胱結石の有病率の増加
      • 研究開発活動の増加
    • 抑制要因
      • 過活動膀胱の新規治療薬に関する認知度の低さ
      • 治療に伴う副作用について
    • 機会
      • 新興国における成長機会
  • COVID-19市場への影響度分析

第4章 過活動膀胱治療市場：薬効クラス別

  • 概要
    • 市場規模・予測
  • 抗コリン作用のある薬剤
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • β-3アドレナリン作動性薬
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • ボトックス
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第5章 過活動膀胱治療市場：疾患タイプ別

  • 概要
    • 市場規模・予測
  • 特発性膀胱過活動
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 神経因性膀胱過活動
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第6章 過活動膀胱治療市場：流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院内薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • ドラッグストア・調剤薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第7章 過活動膀胱治療市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主な動向と機会
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
  • LAMEA
    • 主な動向と機会
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別
      • LAMEAの残りの地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第9章 企業プロファイル

  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd
  • Teva Pharmaceutical Industries Limited
  • Cipla Ltd
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 02. OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 07. OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 10. OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 19. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 20. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 21. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 22. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 38. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 39. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 41. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 42. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 56. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 57. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 58. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 60. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 61. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC.: KEY STRATERGIES
  • TABLE 92. ALEMBIC PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 93. ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 94. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 95. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 96. ALEMBIC PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 97. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 98. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 99. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 100. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 101. ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 102. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 103. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 104. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 105. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 106. DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 107. PFIZER INC.: KEY EXECUTIVES
  • TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 109. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 111. SUMITOMO PHARMA CO., LTD: KEY EXECUTIVES
  • TABLE 112. SUMITOMO PHARMA CO., LTD: COMPANY SNAPSHOT
  • TABLE 113. SUMITOMO PHARMA CO., LTD: PRODUCT SEGMENTS
  • TABLE 114. SUMITOMO PHARMA CO., LTD: PRODUCT PORTFOLIO
  • TABLE 115. SUMITOMO PHARMA CO., LTD: KEY STRATERGIES
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 121. CIPLA LTD: KEY EXECUTIVES
  • TABLE 122. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 123. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 124. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 125. LUPIN: KEY EXECUTIVES
  • TABLE 126. LUPIN: COMPANY SNAPSHOT
  • TABLE 127. LUPIN: PRODUCT SEGMENTS
  • TABLE 128. LUPIN: PRODUCT PORTFOLIO
  • TABLE 129. LUPIN: KEY STRATERGIES
  • TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 132. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 133. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN OVERACTIVE BLADDER TREATMENT MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALOVERACTIVE BLADDER TREATMENT MARKET
  • FIGURE 10. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
  • FIGURE 18. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. OVERACTIVE BLADDER TREATMENT MARKET BY REGION, 2021
  • FIGURE 23. U.S. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: OVERACTIVE BLADDER TREATMENT MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ALEMBIC PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. ASTELLAS PHARMA INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. SUMITOMO PHARMA CO., LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. CIPLA LTD: SALES REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. CIPLA LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A10543

The overactive bladder treatment market valued for $2,426.40 million in 2021 and is estimated to reach $3,465.22 million by 2031, exhibiting a CAGR of 3.6% from 2022 to 2031. 

Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.

Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder. 

For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market.In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.

Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.

In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region. 

In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period.Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth. 

The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers. 

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the overactive bladder treatment market analysis from 2021 to 2031 to identify the prevailing overactive bladder treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the overactive bladder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global overactive bladder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Anti-Cholinergic Drugs
  • Beta-3 adrenergic drugs
  • Botox
  • Others

By Diseases type

  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Korea
    • Rest of LAMEA

Key Market Players

  • AbbVie Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Limited
  • Cipla Ltd
  • Lupin
  • Sumitomo Pharma Co., Ltd
  • Astellas Pharma Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Alembic Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of overactive bladder
      • 3.4.1.2. Increase in prevalence of bladder tumors and bladder stones
      • 3.4.1.3. Increase in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness regarding novel therapeutics for overactive bladder
      • 3.4.2.2. Side effects associated with the treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Anti-Cholinergic Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Beta-3 adrenergic drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Botox
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Idiopathic Bladder Overactivity
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Neurogenic Bladder Overactivity
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: OVERACTIVE BLADDER TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Diseases type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Diseases type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Diseases type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Diseases type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Diseases type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Diseases type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Diseases type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Diseases type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Diseases type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Diseases type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Diseases type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Diseases type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Diseases type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Diseases type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Diseases type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Diseases type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Diseases type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Diseases type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Diseases type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Diseases type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Diseases type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Korea
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Class
      • 7.5.5.3.3. Market size and forecast, by Diseases type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Class
      • 7.5.5.4.3. Market size and forecast, by Diseases type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Alembic Pharmaceuticals Limited
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Astellas Pharma Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Dr. Reddy's Laboratories Ltd.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Sumitomo Pharma Co., Ltd
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Teva Pharmaceutical Industries Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Cipla Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Sun Pharmaceutical Industries Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance